<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39387199</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-2300</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Journal of international medical research</Title><ISOAbbreviation>J Int Med Res</ISOAbbreviation></Journal><ArticleTitle>Risk of COVID-19 infection in patients with NSCLC receiving EGFR-TKI targeted therapy during the first wave in China.</ArticleTitle><Pagination><StartPage>3000605241281907</StartPage><MedlinePgn>3000605241281907</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">03000605241281907</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/03000605241281907</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We examined the factors influencing hospitalization and prognosis among patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) targeted therapy during the first wave of the coronavirus disease 2019 (COVID-19) pandemic.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In total, 267 patients diagnosed with NSCLC who were receiving treatment with third-generation EGFR-TKIs were included in our retrospective study. Data on patients' demographics, clinical characteristics, and survival were collected and analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Over a mean follow-up of 18 months, 80.5% (215/267) of the patients contracted COVID-19, and 12.6% (27/215) of these patients were hospitalized for COVID-19 treatment. Vaccinated patients, those with body mass index (BMI) ≥22.3 kg/m<sup>2</sup>, and those with no comorbidities had lower rates of infection and hospitalization than unvaccinated patients, those with BMI &lt;22.3 kg/m<sup>2</sup>, and those with comorbidities, respectively. Continued NSCLC treatment in patients with COVID-19 was identified as a risk factor for patient survival.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">NSCLC treatment can be continued for patients who received COVID-19 vaccines, those with higher BMI, and those without comorbidities during the COVID-19 epidemic, but treatment interruption might be required for patients during the active phase of infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Peng</ForeName><Initials>P</Initials><Identifier Source="ORCID">0009-0004-6021-1501</Identifier><AffiliationInfo><Affiliation>Lung Cancer Center, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Ling-Ming</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Ultrasound, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jia-Li</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Lung Cancer Center, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Lung Cancer Center, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Yan-Ling</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>Lung Cancer Center, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Lung Cancer Center, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Long</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Lung Cancer Center, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Int Med Res</MedlineTA><NlmUniqueID>0346411</NlmUniqueID><ISSNLinking>0300-0605</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002289" MajorTopicYN="Y">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066246" MajorTopicYN="Y">ErbB Receptors</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="Y">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">body mass index</Keyword><Keyword MajorTopicYN="N">epidermal growth factor receptor tyrosine kinase inhibitor</Keyword><Keyword MajorTopicYN="N">non-small cell lung cancer</Keyword><Keyword MajorTopicYN="N">targeted therapy</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>Declaration of conflicting interestsThe authors declare that there is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>13</Day><Hour>21</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>13</Day><Hour>21</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39387199</ArticleId><ArticleId IdType="pmc">PMC11467978</ArticleId><ArticleId IdType="doi">10.1177/03000605241281907</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Montani D, Savale L, Noel N, et al.. Post-acute COVID-19 syndrome. Eur Respir Rev Off J Eur Respir Soc 2022; 31: 210185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8924706</ArticleId><ArticleId IdType="pubmed">35264409</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang W, Guan W, Chen R, et al.. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21: 335–337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159000</ArticleId><ArticleId IdType="pubmed">32066541</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakoulis VG, Papoutsi E, Siempos II. Effect of Cancer on Clinical Outcomes of Patients With COVID-19: A Meta-Analysis of Patient Data. JCO Glob Oncol 2020; 6: 799–808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7328119</ArticleId><ArticleId IdType="pubmed">32511066</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian J, Yuan X, Xiao J, et al.. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol 2020; 21: 893–903.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7259911</ArticleId><ArticleId IdType="pubmed">32479790</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai M, Liu D, Liu M, et al.. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov 2020; 10: 783–791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7309152</ArticleId><ArticleId IdType="pubmed">32345594</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuderer NM, Choueiri TK, Shah DP, et al.. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 2020; 395: 1907–1918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255743</ArticleId><ArticleId IdType="pubmed">32473681</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang K, Sheng Y, Huang C, et al.. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol 2020; 21: 904–913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7259917</ArticleId><ArticleId IdType="pubmed">32479787</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunski MJ, Burton J, Tawagi K, et al.. Multivariate mortality analyses in COVID-19: Comparing patients with cancer and patients without cancer in Louisiana. Cancer 2021; 127: 266–274.</Citation><ArticleIdList><ArticleId IdType="pubmed">33112411</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q, Luo S, Xie X. The impact of anti-tumor approaches on the outcomes of cancer patients with COVID-19: a meta-analysis based on 52 cohorts incorporating 9231 participants. BMC Cancer 2022; 22: 241. Epub ahead of print 3 April 2022. DOI: 10.1186/s12885-022-09320-x.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8895689</ArticleId><ArticleId IdType="pubmed">35246063</ArticleId></ArticleIdList></Reference><Reference><Citation>Jazieh AR, Akbulut H, Curigliano G, et al.. Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study. JCO Glob Oncol 2020; 6: 1428–1438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7529504</ArticleId><ArticleId IdType="pubmed">32986516</ArticleId></ArticleIdList></Reference><Reference><Citation>Balogun OD, Bea VJ, Phillips E. Disparities in Cancer Outcomes Due to COVID-19-A Tale of 2 Cities. JAMA Oncol 2020; 6: 1531–1532.</Citation><ArticleIdList><ArticleId IdType="pubmed">32789508</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathania AS, Prathipati P, Abdul BA, et al.. COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges. Theranostics 2021; 11: 731–753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7738845</ArticleId><ArticleId IdType="pubmed">33391502</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Jiang M, Qu J, et al.. Clinical management of lung cancer patients during the outbreak of COVID-19 epidemic. Infect Agent Cancer 2020; 15: 56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7509820</ArticleId><ArticleId IdType="pubmed">32983254</ArticleId></ArticleIdList></Reference><Reference><Citation>Deben C, Le Compte M, Siozopoulou V, et al.. Expression of SARS-CoV-2-Related Surface Proteins in Non-Small-Cell Lung Cancer Patients and the Influence of Standard of Care Therapy. Cancers 2022; 14: 4074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9454734</ArticleId><ArticleId IdType="pubmed">36077610</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Elm E, Altman DG, Egger M, et al.. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet Lond Engl 2007; 370: 1453–1457.</Citation><ArticleIdList><ArticleId IdType="pubmed">18064739</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191–2194.</Citation><ArticleIdList><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>Boopathi E, Thangavel C. Dark Side of Cancer Therapy: Cancer Treatment-Induced Cardiopulmonary Inflammation, Fibrosis, and Immune Modulation. Int J Mol Sci 2021; 22: 10126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8465322</ArticleId><ArticleId IdType="pubmed">34576287</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, et al.. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet Lond Engl 2020; 395: 1054–1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera DR, Peters S, Panagiotou OA, et al.. Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. Cancer Discov 2020; 10: 1514–1527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7541683</ArticleId><ArticleId IdType="pubmed">32699031</ArticleId></ArticleIdList></Reference><Reference><Citation>Albiges L, Foulon S, Bayle A, et al.. Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort. Nat Cancer 2020; 1: 965–975.</Citation><ArticleIdList><ArticleId IdType="pubmed">35121871</ArticleId></ArticleIdList></Reference><Reference><Citation>Robilotti EV, Babady NE, Mead PA, et al.. Determinants of COVID-19 disease severity in patients with cancer. Nat Med 2020; 26: 1218–1223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7785283</ArticleId><ArticleId IdType="pubmed">32581323</ArticleId></ArticleIdList></Reference><Reference><Citation>Rüthrich MM, Giessen-Jung C, Borgmann S, et al.. COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry. Ann Hematol 2021; 100: 383–393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7648543</ArticleId><ArticleId IdType="pubmed">33159569</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo D, Wang H, Zhu Q, et al.. Clinical Characteristics of Cancer Patients With COVID-19: A Retrospective Multicentric Study in 19 Hospitals Within Hubei, China. Front Med 2021; 8: 614057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8523781</ArticleId><ArticleId IdType="pubmed">34676221</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldani S, Petrelli F, Dognini G, et al.. COVID-19 and Lung Cancer Survival: An Updated Systematic Review and Meta-Analysis. Cancers (Basel) 2022; 14: 5706. Epub ahead of print 21 November 2022. DOI: 10.3390/cancers14225706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9688481</ArticleId><ArticleId IdType="pubmed">36428798</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavez-MacGregor M, Lei X, Zhao H, et al.. Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer. JAMA Oncol 2022; 8: 69–78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8554684</ArticleId><ArticleId IdType="pubmed">34709356</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee LY, Cazier JB, Angelis V, et al.. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet Lond Engl 2020; 395: 1919–1926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255715</ArticleId><ArticleId IdType="pubmed">32473682</ArticleId></ArticleIdList></Reference><Reference><Citation>Che K, Hong C, He Y, et al.. Association of immune-related adverse events with COVID-19 pneumonia in lung cancer patients receiving immune checkpoint inhibitors: a cross-sectional study in China. BMC Cancer 2023; 23: 1069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10629076</ArticleId><ArticleId IdType="pubmed">37932685</ArticleId></ArticleIdList></Reference><Reference><Citation>Yekedüz E, Utkan G, Ürün Y. A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19. Eur J Cancer 2020; 141: 92–104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7538140</ArticleId><ArticleId IdType="pubmed">33130550</ArticleId></ArticleIdList></Reference><Reference><Citation>Allegrezza MJ, Conejo-Garcia JR. Targeted Therapy and Immunosuppression in the Tumor Microenvironment. Trends Cancer 2017; 3: 19–27.</Citation><ArticleIdList><ArticleId IdType="pubmed">28718424</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai YJ, Hu F, Li H, et al.. A profiling analysis on the receptor ACE2 expression reveals the potential risk of different type of cancers vulnerable to SARS-CoV-2 infection. Ann Transl Med 2020; 8: 481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7210193</ArticleId><ArticleId IdType="pubmed">32395525</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M, Martin JC. Author Correction: Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 2020; 20: 448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7265161</ArticleId><ArticleId IdType="pubmed">32488203</ArticleId></ArticleIdList></Reference><Reference><Citation>Stebbing J, Phelan A, Griffin I, et al.. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 2020; 20: 400–402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7158903</ArticleId><ArticleId IdType="pubmed">32113509</ArticleId></ArticleIdList></Reference><Reference><Citation>Buske C, Dreyling M, Alvarez-Larrán A, et al.. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. ESMO Open 2022; 7: 100403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8795783</ArticleId><ArticleId IdType="pubmed">35272130</ArticleId></ArticleIdList></Reference><Reference><Citation>Raad II, Hachem R, Masayuki N, et al.. International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: impact of risk factors and treatment modalities on survivorship. Elife 2023; 12: e81127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9981148</ArticleId><ArticleId IdType="pubmed">36715684</ArticleId></ArticleIdList></Reference><Reference><Citation>Garassino MC, Whisenant JG, Huang LC, et al.. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol 2020; 21: 914–922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7292610</ArticleId><ArticleId IdType="pubmed">32539942</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020; 323: 1239–1242.</Citation><ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, Guo H, Zhou P, et al.. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021; 19: 141–154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergman J, Ballin M, Nordström A, et al.. Risk factors for COVID-19 diagnosis, hospitalization, and subsequent all-cause mortality in Sweden: a nationwide study. Eur J Epidemiol 2021; 36: 287–298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7946619</ArticleId><ArticleId IdType="pubmed">33704634</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao M, Piernas C, Astbury NM, et al.. Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study. Lancet Diabetes Endocrinol 2021; 9: 350–359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8081400</ArticleId><ArticleId IdType="pubmed">33932335</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Q, Chen F, Wang T, et al.. Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China. Diabetes Care 2020; 43: 1392–1398.</Citation><ArticleIdList><ArticleId IdType="pubmed">32409502</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin T, Li Y, Ying Y, et al.. Prevalence of comorbidity in Chinese patients with COVID-19: systematic review and meta-analysis of risk factors. BMC Infect Dis 2021; 21: 200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7897883</ArticleId><ArticleId IdType="pubmed">33618678</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S, Zhuang Q, Chiang J, et al.. Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and meta-analysis. BMJ Open 2022; 12: e044661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8822543</ArticleId><ArticleId IdType="pubmed">35131810</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Chen X, Cai Y, et al.. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020; 180: 934–943.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7070509</ArticleId><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt AL, Labaki C, Hsu CY, et al.. COVID-19 vaccination and breakthrough infections in patients with cancer. Ann Oncol 2022; 33: 340–346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8704021</ArticleId><ArticleId IdType="pubmed">34958894</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinato DJ, Aguilar-Company J, Ferrante D, et al.. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. Lancet Oncol 2022; 23: 865–875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9162476</ArticleId><ArticleId IdType="pubmed">35660139</ArticleId></ArticleIdList></Reference><Reference><Citation>Valanparambil RM, Carlisle J, Linderman SL, et al.. Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. J Clin Oncol 2022; 40: 3808–3816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9671759</ArticleId><ArticleId IdType="pubmed">35759727</ArticleId></ArticleIdList></Reference><Reference><Citation>Butt AA, Nafady-Hego H, Chemaitelly H, et al.. Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination. Int J Infect Dis 2021; 110: 353–358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8349447</ArticleId><ArticleId IdType="pubmed">34375762</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J 2020; 41: 3038–3044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7470753</ArticleId><ArticleId IdType="pubmed">32882706</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M, Verleden SE, Kuehnel M, et al.. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med 2020; 383: 120–128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7412750</ArticleId><ArticleId IdType="pubmed">32437596</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrott B, Head R, Pringle KG, et al.. “LONG COVID”—A hypothesis for understanding the biological basis and pharmacological treatment strategy. Pharmacol Res Perspect 2022; 10: e00911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8929332</ArticleId><ArticleId IdType="pubmed">35029046</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart CA, Gay CM, Ramkumar K, et al.. Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. J Thorac Oncol 2021; 16: 1821–1839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8282443</ArticleId><ArticleId IdType="pubmed">34274504</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>